2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety
作者:Cameron J. Smith、Amjad Ali、Liya Chen、Milton L. Hammond、Matt S. Anderson、Ying Chen、Suzanne S. Eveland、Qiu Guo、Sheryl A. Hyland、Denise P. Milot、Carl P. Sparrow、Samuel D. Wright、Peter J. Sinclair
DOI:10.1016/j.bmcl.2009.10.099
日期:2010.1
A series of 2-arylbenzoxazole inhibitors of the cholesterol ester transfer protein (CETP) is described. Structure-activity studies focused on variation of the substitution of the benzoxazole moiety. Substitution at the 5- and 7-positions of the benzoxazole moiety was found to be beneficial for CETP inhibition. Compound 47 was found to be the most potent inhibitor in this series and inhibited CETP with an IC50 of 28 nM. (C) 2009 Elsevier Ltd. All rights reserved.
SALTS OF PAROXETINE
申请人:SMITHKLINE BEECHAM PLC
公开号:EP1091958A1
公开(公告)日:2001-04-18
CETP INHIBITORS
申请人:Merck & Co., Inc.
公开号:EP1954287A2
公开(公告)日:2008-08-13
Cetp Inhibitors
申请人:Ali Amjad
公开号:US20090264405A1
公开(公告)日:2009-10-22
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.